Conference Program Home
  My Program

All Times EDT

CC = Walter E. Washington Convention Center   M = Marriott Marquis Washington, DC
* = applied session       ! = JSM meeting theme

Activity Details

153 Mon, 8/8/2022, 10:30 AM - 12:20 PM CC-Hall D
Contributed Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Gyuhyeong Goh, Kansas State University
1: Some Statistical Considerations in In-Vitro Data Analysis
Dalong Huang, FDA/CDER; Jing Sun, FDA/CDER; Sheng Yuan, University of Kentucky
2: Dynamic Prediction of Residual Life with Longitudinal Covariates Using Long Short-Term Memory Networks
Grace Rhodes, North Carolina State University; Wenbin Lu, North Carolina State University; Marie Davidian, North Carolina State University
3: Randomization Based Methods for Covariance and Stratified Adjustment of Win Ratios and Win Odds for Ordinal Outcomes
Ann Marie K. Weideman, University of North Carolina at Chapel Hill, Chapel Hill, NC; Gary G. Koch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Elaine K. Kearney, University of North Carolina at Chapel Hill, Chapel Hill, NC
4: The Win Ratio Approach for Recurrent Events with an Associated Terminal Event - Simulations and Considerations
Huihua Li, Pfizer Inc; Anqi Yin, Georgetown University; Ching-Ray Yu, Pfizer, Inc
5: Statistical Methods for Selective Biomarker Testing
Natalie DelRocco, University of Florida; Adam Ding, Northeastern University; Samuel Wu, University of Florida
6: Projection in Site-Specific Participants Enrollment for Clinical Trials
Wenjun He, EMMES LLC
7: Adaptive Two-Stage Designs for One-Arm Binary Endpoint in Oncology Clinical Trials
Yu Zhao, University of California, San Diego; Weichao Bao, Bayer U.S. LLC; Kui Shen, Bayer U.S. LLC
8: A Unified Bayesian Framework for Assessing Predictive Probability of Trial Success
Archie Sachdeva, University of Florida; Ming Zhou, Bristol Myers Squibb; Ram Tiwari, Bristol Myers Squibb
9: A Single-Arm Multiple-Stage Bayesian-Frequentist Design with Efficacy and Futility Boundaries
Bing Liu, KUMC; Jianghua He, University of Kansas Medical Center
10: Jointly Assessing the Overall Treatment Effects Across Multiple Timepoints by a Global Test in the Paradigm of Longitudinal Analysis
Hong Li, Takeda
11: An Exact Confidence Interval of Observed Proportion with Stratified Factors
ruji yao, Merck & Co., Inc.; Amarjot Kaur, Merck & Co; qing li, Merck & co., Inc.
12: Multiple Imputation of COVID-19 Disease Progression Using a Markov Model
Chaoran Hu, Eli Lilly and Company; Nathan Morris, Eli Lilly and Company; Sujatro Chakladar, Eli Lilly and Company; Brenda Crowe, Eli Lilly and Company
13: Doubly-Robust Estimation for Interim Monitoring in Sequential Multiple Assignment Randomized Trials
Cole Manschot, North Carolina State University; Marie Davidian, North Carolina State University; Eric Laber, Duke University
14: Survey and Recommendations on the Use of P-Values Driving Decisions in Nonclinical Applications
Stan Altan, Janssen R&D; Helena Geys, Janssen R&D ; Steven Novick, Astra Zeneca R&D
15: Interim Presentation and Analysis of Multi-Protocol Clinical Trials
Scott Diegel, University of Wisconsin-Madison; Melissa Schultz, University of Wisconsin-Madison; Nick Zaborek, University of Wisconsin-Madison
16: Current Situation and Consideration on Sample Size Re-Estimation
Shunichiro Orihara, Kyowa Kirin Co., Ltd.; Yuji Tanaka, Kyowa Kirin Co., Ltd.; Junji Moriya, Kyowa Kirin Co., Ltd.
17: BACPAC Modified CDISC Standards Facilitate Characterization of Patient Populations and Integration of Data Across Multiple Back Pain Studies
Anna Batorsky, University of North Carolina Chapel Hill; Micah McCumber, University of North Carolina Chapel Hill; Charity G. Patterson, Dept of Physical Therapy School of Health & Rehabilitation Sciences Univ of Pittsburgh; Matthew A. Psioda, University of North Carolina at Chapel Hill